PURPOSE: Tumor genomic profiling (TGP) can reveal secondary findings about inherited disease risks in a patient with cancer. Little is known about how patients with advanced cancer, currently the primary users of TGP, perceive the benefits and harms of secondary germline findings. METHODS: We conducted semistructured interviews with 40 patients with advanced breast, bladder, colorectal, or lung cancer who had TGP. Qualitative interview data were evaluated by using a thematic content analysis approach. RESULTS: Most participants expressed interest in the prospect of learning their secondary germline findings (57%), although a minority was equivocal (29%) or disinterested (14%). Reasons for these preferences varied but were influenced by participants' perceptions of diverse benefits and harms of this information, which they regarded as relevant to themselves; their families; and other patients with cancer, medical science, and society. These attitudes were uniquely shaped by participants' personal disease experiences and health status. CONCLUSION: Many patients with advanced cancer are interested in learning secondary germline findings and hold optimistic and perhaps unrealistic beliefs about the potential health benefits. Patients also have important concerns about clinical and emotional implications of this information. These perceptions are necessary to address to ensure that patients make informed decisions about learning secondary germline findings.
PURPOSE: Tumor genomic profiling (TGP) can reveal secondary findings about inherited disease risks in a patient with cancer. Little is known about how patients with advanced cancer, currently the primary users of TGP, perceive the benefits and harms of secondary germline findings. METHODS: We conducted semistructured interviews with 40 patients with advanced breast, bladder, colorectal, or lung cancer who had TGP. Qualitative interview data were evaluated by using a thematic content analysis approach. RESULTS: Most participants expressed interest in the prospect of learning their secondary germline findings (57%), although a minority was equivocal (29%) or disinterested (14%). Reasons for these preferences varied but were influenced by participants' perceptions of diverse benefits and harms of this information, which they regarded as relevant to themselves; their families; and other patients with cancer, medical science, and society. These attitudes were uniquely shaped by participants' personal disease experiences and health status. CONCLUSION: Many patients with advanced cancer are interested in learning secondary germline findings and hold optimistic and perhaps unrealistic beliefs about the potential health benefits. Patients also have important concerns about clinical and emotional implications of this information. These perceptions are necessary to address to ensure that patients make informed decisions about learning secondary germline findings.
Authors: Christopher A Cassa; Sarah K Savage; Patrick L Taylor; Robert C Green; Amy L McGuire; Kenneth D Mandl Journal: Genome Res Date: 2012-01-06 Impact factor: 9.043
Authors: Stacy W Gray; Katherine Hicks-Courant; Christopher S Lathan; Levi Garraway; Elyse R Park; Jane C Weeks Journal: J Oncol Pract Date: 2012-08-07 Impact factor: 3.840
Authors: Susan M Wolf; Frances P Lawrenz; Charles A Nelson; Jeffrey P Kahn; Mildred K Cho; Ellen Wright Clayton; Joel G Fletcher; Michael K Georgieff; Dale Hammerschmidt; Kathy Hudson; Judy Illes; Vivek Kapur; Moira A Keane; Barbara A Koenig; Bonnie S Leroy; Elizabeth G McFarland; Jordan Paradise; Lisa S Parker; Sharon F Terry; Brian Van Ness; Benjamin S Wilfond Journal: J Law Med Ethics Date: 2008 Impact factor: 1.718
Authors: Rafeek A Yusuf; Deevakar Rogith; Shelly R A Hovick; Susan K Peterson; Allison M Burton-Chase; Bryan M Fellman; Yisheng Li; Carolyn McKinney; Elmer V Bernstam; Funda Meric-Bernstam Journal: Cancer Date: 2014-09-10 Impact factor: 6.860
Authors: Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Denalee M O'Malley; Cindy K Blair; Alissa Greenbaum; Charles L Wiggins; Ashwani Rajput; Vi K Chiu; Anita Y Kinney Journal: J Community Genet Date: 2022-01-08
Authors: Ilana B Solomon; Sarah McGraw; Jenny Shen; Adem Albayrak; Gil Alterovitz; Melanie Davies; Catherine Del Vecchio Fitz; Rachel A Freedman; Lisa N Lopez; Lynette M Sholl; Eliezer Van Allen; Joanne Mortimer; Marwan Fakih; Sumanta Pal; Karen L Reckamp; Yuan Yuan; Stacy W Gray Journal: JCO Precis Oncol Date: 2020-04-14
Authors: Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng Journal: JCO Precis Oncol Date: 2018-08-16
Authors: Jada G Hamilton; Elyse Shuk; Margaux Genoff Garzon; Vivian M Rodríguez; Joy Westerman; Jennifer L Hay; Kenneth Offit; Mark E Robson Journal: JCO Precis Oncol Date: 2017-12-21
Authors: Salma Shickh; Marc Clausen; Chloe Mighton; Mariana Gutierrez Salazar; Kathleen-Rose Zakoor; Rita Kodida; Emma Reble; Christine Elser; Andrea Eisen; Seema Panchal; Melyssa Aronson; Tracy Graham; Susan Randall Armel; Chantal F Morel; Ramzi Fattouh; Emily Glogowski; Kasmintan A Schrader; Jada G Hamilton; Kenneth Offit; Mark Robson; June C Carroll; Wanrudee Isaranuwatchai; Raymond H Kim; Jordan Lerner-Ellis; Kevin E Thorpe; Andreas Laupacis; Yvonne Bombard Journal: BMJ Open Date: 2019-10-07 Impact factor: 2.692
Authors: Kenneth Offit; Kaitlyn A Tkachuk; Zsofia K Stadler; Michael F Walsh; Hector Diaz-Zabala; Jeffrey D Levin; Zoe Steinsnyder; Vignesh Ravichandran; Ravi N Sharaf; Melissa K Frey; Steven M Lipkin; Mark E Robson; Jada G Hamilton; Joseph Vijai; Semanti Mukherjee Journal: J Clin Oncol Date: 2020-01-10 Impact factor: 50.717